Other acute conditions (e.g., acute pancreatitis and sepsis), decreased kallistatin levels might reflect increased consumption, driven by its binding to released tissue kallikrein or glycosaminoglycans (such as kallistatin, plasminogen activator inhibitor-1, and α1-antitrypsin) (10). This evidence concerns the gene KLK1 and acute pancreatitis.